One should acknowledge the excellent performance status of patients with newly diagnosed breast cancer as well as the fact that endocrine combinations with novel oral agents, particularly inhibitors of the cyclin dependent kinase 4 and 6 (CDK4/6), can yield similarly high rates of molecular downstaging with fewer toxicities [39]. The gene discussed is CDK4; the disease is breast cancer.